Bruker Announces Major Advancements at AGBT to Enable Complete High-Fidelity Spatial Biology Across the Biological Spectrum

ORLANDO, Fla.--(BUSINESS WIRE)--Feb 23, 2026--

Bruker Corporation (Nasdaq: BRKR) announced today significant portfolio advancements from Bruker Spatial Biology to be unveiled at the 2026 Advances in Genome Biology and Technology (AGBT) General Meeting. These updates highlight Bruker’s category leadership in spatial biology and its commitment to delivering best‑in‑class solutions across DNA, RNA, and protein. The Bruker Spatial Biology division will launch several new products, introduce expanded capabilities, and demonstrate a strong innovation roadmap that extends its technical leadership in each spatial platform, and further integrates multiomics across platforms to accelerate scientific insights — from discovery through translational research.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260223770073/en/

Bruker’s spatial biology portfolio now includes the unique PaintScape ™ platform, GeoMx ® Digital Spatial Profiler (DSP), the high-plex CosMx ® Spatial Molecular Imager (SMI) spatial transcriptomics/multiomics platform with whole transcriptome coverage, the new CellScape ™ XR spatial proteomics platform, and the expanded AtoMx ® Spatial Informatics Platform (SIP). Together, these broad and deep spatial biology capabilities form a comprehensive suite that enables researchers to visualize and quantify biology across every layer with unmatched information depth and resolution, designed to work together as a cohesive multiomic ecosystem.

PaintScape Now Open for Pre‑Orders with Shipments Beginning This Spring

Bruker is now accepting pre-orders for the PaintScape system, a first and only high precision platform enabling multiplexed, direct visualization of the 3D genome in situ in single cells. PaintScape enables the unprecedented study of genome organization and structure, allowing researchers to visualize chromosomal organization and investigate how spatial genome structural variations influence gene dysregulation and disease biology. At AGBT, Bruker will present first-of-its-kind 3D genome visualization on both cell lines and intact fresh frozen (FF) tissue using the PaintScape platform.

Bruker will launch two new panels for the PaintScape platform, including the ChromoPaint™ HuCL PanChromo MPX panel, a 419-plex panel designed for genome wide in situ visualization of chromosomal organization in human cell lines. In addition, Bruker will announce the OncoPaint™ Oncogenic Pathways Panels that will be available later this year, a 1000+-plex modular panel designed to combine genome wide chromosome painting with painting of select cancer pathway associated gene regions in increased genomic resolution.

Commercial shipments of the PaintScape platform are expected to begin this spring.

Introducing CellScape XR, the Highest Performing Spatial Proteomics Ecosystem Delivering Best-in-Class Data Fidelity, Robustness and Flexibility

Bruker will debut CellScape XR, the next generation of its precise spatial proteomics platform. CellScape XR combines major advancements across instrumentation, software, and the assay ecosystem to deliver best-in-class data quality, dramatically expand available markers, more than double throughput, with further improved robustness and flexibility. This includes improvements in optics and imaging chamber design, which combined with EpicIF™ technology, enables rapid whole-slide signal removal between staining cycles within seconds. The launch also includes expanded VistaPlex™ multiplex assay kits, building on hardware improvements that enable use of a broader range of fluorophore conjugated antibodies, and a PowerOMX™ data engine for improved data processing.

“The launch of CellScape XR demonstrates Bruker’s commitment to leading innovation in spatial biology. These advancements will enhance the translational and clinical potential of the CellScape platform and help our customers advance their science to drive meaningful patient impact,” said Thomas Campbell, PhD, Senior Director of Product Management at Bruker Spatial Biology.

Additionally, the CellScape XR launch includes a significantly expanded menu of VistaPlex assay kits, comprised of primary fluorescently labelled antibodies for robust assay performance. With Bruker’s proprietary EpicIF technology, fluorescence signal from any organic fluorophore can be removed, enabling users to customize VistaPlex panels with a wide range of directly conjugated antibodies. As an add-on to the VistaPlex kits, Bruker will offer a new universal antibody labeling capability, VistaFlex™, developed in collaboration with Proteintech ® Group, enabling use of virtually any IHC-validated unlabeled antibody on the market without the need for antibody stripping, as required by other platforms, thus broadening assay design freedom and opening access to a wider range of protein targets and application‑specific antibodies.

Pre‑orders begin at AGBT, with commercial shipments expected this summer.

CosMx SMI Extends Complete Spatial Biology Approach to miRNA, TCR, and Mouse Whole Transcriptome

Bruker’s CosMx SMI delivers the most complete single-cell and subcellular spatial transcriptomic view of human biology through multiomic imaging of the whole transcriptome (WTX) plus 64+ proteins from a single FFPE or FF tissue section.

Bruker now extends their complete biology approach to mouse research by announcing development of the CosMx Mouse Whole Transcriptome (WTX) assay. The mouse WTX assay will be available for both FFPE and FF tissues with early access through Bruker’s Technology Access Program this spring and full commercial availability later this year.

Bruker additionally unveils plans for commercial high-plex spatial miRNA and T-Cell Receptor (TCR) assays at subcellular resolution. The new miRNA assay will enable researchers to jointly interrogate mRNA, protein, and miRNA from the same cell, delivering a more complete multiomic view of gene regulation, post-transcriptional control, and cell state transitions. The TCR assay for the study of variable–diversity–joining mRNA expression will provide a new layer of in-depth immune biology in addition to whole transcriptome imaging.

AtoMx SIP Leverages Complete Biology Layers for Image-First Experience, AI-Ready Data, and 3D Cell Segmentation

Bruker’s AtoMx platform designed to accelerate study-level insights from CosMx SMI data now introduces a spatial discovery mode for rapid image-based exploration of subcellular and single-cell whole transcriptome data. This new experience pre-calculates spatial insights as well as prepares data exports for conversational large language models (LLM). Applying LLMs to the comprehensive data of CosMx SMI results in richer and higher quality LLM outputs than would be possible with any other commercial spatial assay and platform, giving researchers the most complete interactive experience for biological understanding.

Bruker introduces 3D AI cell segmentation models to AtoMx SIP, extending their best-in-class definition of single-cell boundaries for accurate RNA transcript assignment in space. This advancement addresses long-standing limitations of other platforms and cell segmentation algorithms that do not account for overlapping cells in tissue sections.

GeoMx Discovery Multiomics Platform Showcases Unmatched Spatial Biomarker Discovery at Scale with Whole Transcriptome and 1200+ Protein Targets

Bruker’s GeoMx DSP enables large-cohort interrogation of the whole transcriptome and the Discovery Proteome Atlas (DPA), a spatial assay profiling more than 1,200 protein targets. At AGBT, researchers will present applications ranging from oncology to neuroscience, demonstrating how GeoMx DSP opens the possibilities for spatial biomarker discovery at scale.

Bruker additionally introduces a cross-platform GeoMx DPA and CellScape XR workflow from the same tissue section that presents an unprecedented opportunity for spatial protein biomarker discovery to subsequent validation and translational studies.

Collaborations Demonstrate the Importance of High Fidelity, Complete Biology

Bruker also announces a new collaboration with the University of Glasgow to establish a Bruker Spatial Biology Center of Excellence, led by Dr. Nigel Jamieson. The collaboration will generate one of the largest spatially profiled pancreatic cancer cohorts to date, imaging more than 1000 patient samples using the CellScape platform, CosMx SMI and GeoMx DSP. This effort aims to build large-scale data models to study cancer progression, tumor-immune interactions and tissue architecture at unprecedented resolution. The Center of Excellence will serve as a platform for advancing multiomic discovery and developing new approaches for large-cohort spatial analysis in translational research.

Join Bruker at AGBT 2026

Bruker will share more details on these innovations at the AGBT hospitality suite in Dade Lounge throughout the week and in their Silver Sponsor Workshop on Wednesday, February 25.

For more information, please visit www.brukerspatialbiology.com.

About Bruker Corporation – Leader of the Post-Genomic Era

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

CosMx Same-Cell Multiomics with CosMx WTX and protein from lung tissue

Human FFPE intestinal biopsy stained on CellScape XR

PaintScape in situ single cell chromosome traces from the 419-plex ChromoPaint HuCL PanChromo MPX panel

THE HAGUE, Netherlands (AP) — Prosecutors at the International Criminal Court told judges on Monday that former Philippine President Rodrigo Duterte encouraged death squads to carry out extrajudicial killings using fear and financial rewards.

The court in The Hague is holding pretrial hearings for the ex-leader, who is facing three counts of crimes against humanity for deadly anti-drugs crackdowns he oversaw while in office.

According to prosecutors, police and hit squad members carried out dozens of murders at Duterte's behest, motivated by the promise of money or to avoid becoming targets themselves. “For some, killing reached the level of a perverse form of competition,” deputy prosecutor Mame Mandiaye Niang said in his opening statement.

The charges date from Duterte’s time as mayor of the southern Philippine city of Davao and later as president, and include dozens of killings as part of his so-called war on drugs.

The hearing is not a trial, but allows prosecutors to outline their case in court. After weighing the evidence, judges have 60 days to decide whether it is strong enough to merit putting Duterte on trial.

Duterte “stands behind his legacy resolutely, and he maintains his innocence absolutely,” lead defense lawyer Nick Kaufman told the three-judge panel.

According to Kaufman, the prosecution “cherry-picked” examples of Duterte “bombastic rhetoric," and his client's words were never intended to incite violence.

Duterte, 80, was not present in the courtroom, having waived his right to appear. Last month, judges found he was fit to stand trial, after postponing an earlier hearing over concerns about his health.

In the Philippines, dozens of activists with relatives of suspects killed in Duterte’s anti-drugs crackdowns held a noisy protest in metropolitan Manila on Monday. More than 100 relatives gathered to watch the pretrial hearings on big TV screens in three venues organized by civic groups in the capital region.

“We’re hoping that the ICC, even if it’s thousands of miles away, will finally render justice to all these families,” said Randy delos Santos, a volunteer in a charity shelter which was hosting one event.

The 17-year-old nephew of delos Santos was shot and killed by three police officers in a purported drug raid in August 2017. The killing sparked a public outcry. The officers were found guilty of murder in a rare conviction by a Manila court the following year.

Duterte supporters criticized the administration of current Philippine President Ferdinand Marcos Jr., Duterte’s political rival, for arresting and surrendering the former leader to a court whose jurisdiction they dispute. Detractors include Duterte's daughter, current Philippine Vice President Sara Duterte who announced last week that she would seek the presidency in the 2028 elections.

ICC prosecutors said in February 2018 that they would open a preliminary investigation into the violent drug crackdowns. In a move that human rights activists say was aimed at escaping accountability, Duterte, who was president at the time, announced a month later that the Philippines would leave the court.

Judges rejected a request from Duterte’s legal team to throw out the case on the grounds that the court did not have jurisdiction because of the Philippine withdrawal. Countries can’t “abuse” their right to withdraw from the court's foundational Rome Statute “by shielding persons from justice in relation to alleged crimes that are already under consideration,” the September decision says.

An appeal of that decision is still pending.

Estimates of the death toll during Duterte’s presidential term vary, from the more than 6,000 that the national police have reported to up to 30,000 claimed by human rights groups.

———

Associated Press journalist Jim Gomez in Manila contributed to this report

Families of victims on the deadly anti-drugs crackdowns of former Philippine President Rodrigo Duterte watch a live stream of Duterte's pre-trial hearing from The Hague, at a venue in Quezon City, Philippines on Monday, Feb. 23, 2026. (AP Photo/Aaron Favila)

Activists hold pictures of former Philippine President Rodrigo Duterte during a rally before they watch a live stream of Duterte's confirmation hearing from The Hague, at a venue in Quezon City, Philippines on Monday, Feb. 23, 2026. Sign reads "Hold Duterte accountable."(AP Photo/Aaron Favila)

FILE - Former President of the Philippines Rodrigo Duterte speaks inside the Southorn Stadium during a thanksgiving gathering organized by Hong Kong-based Filipino workers for the former populist president in Hong Kong on March 9, 2025. (AP Photo/Vernon Yuen, File)